Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia
Chronic myelomonocytic leukemia (CMML) is an aggressive myeloid neoplasm in which treatment strategies with the capacity to improve survival are currently lacking. Clinical features are heterogeneous and although the overall prognosis is poor, survival can vary significantly between individuals. This reflects the need for an individualized treatment approach which incorporates accurate risk stratification. Though numerous prognostic scores exist, newer CMML-specific models incorporating molecular data should be favored. While asymptomatic, low-risk patients should be observed until their disease progresses, the majority of patients will require treatment. Due to a deficiency in treatments with disease-modifying capacity, any patient who requires treatment should be considered for enrollment in clinical trials evaluating novel therapeutic approaches. Allogeneic stem cell transplant (allo-SCT) remains the only current therapy with the potential to cure the disease and should be considered in most patients with intermediate- to high-risk disease. However, substantial risks are involved and, in part, because of advanced age at diagnosis, a minority of patients are candidates. Hypomethylating agents (HMAs) have become a preferred treatment approach, and should be used in those with cytopenias. Patients presenting with proliferative features can be treated with hydroxyurea to manage their symptoms and control leukocytosis, though HMAs can be incorporated as well, particularly in patients with higher risk disease. HMAs should also be considered in patients with a high burden of disease prior to proceeding with allo-SCT. Induction chemotherapy should be reserved for younger, healthy patients who have transformed to acute myeloid leukemia to induce remission prior to transplant. Supportive care utilizing transfusion support, erythropoiesis-stimulating agents, and infection prevention measures should be incorporated into the care of all patients.
KeywordsCMML Leukemia MDS/MPN
Compliance with Ethical Standards
Conflict of Interest
Anthony M. Hunter declares that he has no conflict of interest.
Ling Zhang declares that she has no conflict of interest.
Eric Padron has received research funding from Kura Oncology, Incyte Corporation, and KaloBios Pharmaceuticals.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544. This is the most recent update to the WHO classification of myeloid malignancies, published in 2016, and contains the current criteria required to establish a diagnosis of CMML.CrossRefGoogle Scholar
- 4.Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52. https://doi.org/10.1182/blood-2008-01-134858.CrossRefPubMedGoogle Scholar
- 5.Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium study. Am J Hematol. 2014;89(12):1111–5. https://doi.org/10.1002/ajh.23846.CrossRefPubMedGoogle Scholar
- 7.Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–12. https://doi.org/10.1038/leu.2014.125.CrossRefPubMedGoogle Scholar
- 9.• Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333. https://doi.org/10.1038/bcj.2015.53. Our group evaluated seven different prognostic scoring systems in a large cohort of 1800 patients and found that all systems were valid and comparable, though none of these included somatic mutations. This paper also validated the negative prognostic impact of ASXL1 mutation and, for the first time, identified an inferior OS associated with mutation in CBL. CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731–2; author reply 2–3.Google Scholar
- 13.Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351–61. https://doi.org/10.1002/cncr.23697.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.• Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–17. https://doi.org/10.1182/blood-2016-05-714030. The CPSS-Mol model is the most recently created prognostic model and the most comprehensive with regard to incorporation of genetic information. It utilizes a genetic score that includes cytogenetics as well as the mutation status of ASXL1, RUNX1, NRAS, and SETBP1. CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9. https://doi.org/10.1182/blood-2005-05-2004.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.•• Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171(2):239–46. https://doi.org/10.1111/bjh.13576. Although there is no prospective data on allo-SCT in CMML, this is the largest retrospective series reported to date, with 513 patients included. Published by the European Group for Blood and Marrow Transplantation, 4-year OS and relapse-free survival of 33% and 27%, respectively, were observed.CrossRefPubMedGoogle Scholar
- 20.Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17(6):908–15. https://doi.org/10.1016/j.bbmt.2010.09.018.CrossRefPubMedGoogle Scholar
- 21.Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21):2662–70. https://doi.org/10.1200/JCO.2012.46.8652.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003;21(16):3060–5. https://doi.org/10.1200/JCO.2003.02.057.CrossRefPubMedGoogle Scholar
- 23.Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108(3):836–46. https://doi.org/10.1182/blood-2005-11-4503.CrossRefPubMedGoogle Scholar
- 24.Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 2002;119(1):144–54.CrossRefGoogle Scholar
- 26.Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol. 2012;30(36):4533–40. https://doi.org/10.1200/JCO.2012.44.3499.CrossRefPubMedGoogle Scholar
- 29.• Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2016;22(1):47–53. https://doi.org/10.1016/j.bbmt.2015.08.031. Although most evidence in this area is extrapolated from MDS patients, this study evaluated therapies preceding allo-SCT in 83 patients with CMML. Treatment with a HMA and achievement of bone marrow blasts < 5% prior to transplant were associated with improved PFS.CrossRefPubMedGoogle Scholar
- 32.Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429–40. https://doi.org/10.1200/JCO.2002.04.117.CrossRefPubMedGoogle Scholar
- 34.Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32. https://doi.org/10.1016/S1470-2045(09)70003-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma. 2013;54(3):658–61. https://doi.org/10.3109/10428194.2012.719617.CrossRefPubMedGoogle Scholar
- 43.•• Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413–8. https://doi.org/10.1038/leu.2017.186. This is the most recently published phase 2 study evaluating HMA use in a CMML-specific population. Forty-three predominantly high-risk patients were treated with decitabine with an overall response rate of 47% and median OS of 17 months, with a significant improvement in OS observed in responders (31 months in those with CR). No somatic mutation was predictive of response.CrossRefPubMedGoogle Scholar
- 44.Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–52. https://doi.org/10.1038/leu.2011.71.CrossRefPubMedGoogle Scholar
- 47.• Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017;92(7):599–606. https://doi.org/10.1002/ajh.24735. This is a large retrospective analysis of 151 CMML patients treated with HMA at a single institution. Several predictors of improved OS were observed, as was a higher rate of CR in those treated with decitabine compared to azacitidine (58.3% vs. 20.6%, p < 0.001). A dismal prognosis after HMA failure was identified, with median OS of 7 months after relapse.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Garcia-Manero G, Griffiths EA, Roboz GJ, Busque L, Wells RA, Odenike O, et al. A phase 2 dose-confirmation study of oral ASTX727, a combination of oral decitabine with a cytidine deaminase inhibitor (CDAi) cedazuridine (E7727), in subjects with myelodysplastic syndromes (MDS). Blood. 2017;130(Suppl 1):4274.Google Scholar
- 49.Savona MR, Kolibaba K, Conkling P, Kingsley EC, Becerra C, Morris JC, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018. https://doi.org/10.1002/ajh.25216.
- 53.Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109(6):1133–7. https://doi.org/10.1002/cncr.22508.CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007;12(10):1264–73. https://doi.org/10.1634/theoncologist.12-10-1264.CrossRefPubMedGoogle Scholar
- 56.List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134–9. https://doi.org/10.1200/JCO.2010.34.1222.CrossRefPubMedGoogle Scholar
- 59.Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016;30(4):889–96. https://doi.org/10.1038/leu.2015.265.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Garcia-Manero G, Savona MR, Gore SD, Scott BL, Cogle CR, Boyd T, et al. CC-486 (oral azacitidine) in patients with hematological malignancies who had received prior treatment with injectable hypomethylating agents (HMAs): results from phase 1/2 CC-486 studies. Blood. 2016;128(22):905.Google Scholar
- 61.Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1099–110. https://doi.org/10.1016/S1470-2045(15)00038-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, et al. Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. J Clin Oncol. 2017;35(15_suppl):7020. https://doi.org/10.1200/JCO.2017.35.15_suppl.7020.CrossRefGoogle Scholar
- 63.Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121(25):5068–77. https://doi.org/10.1182/blood-2012-10-460170.CrossRefPubMedPubMedCentralGoogle Scholar
- 64.• Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, et al. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res. 2016;22(15):3746–54. https://doi.org/10.1158/1078-0432.CCR-15-2781. The results of a phase 1 study of ruxolitinib in CMML, which demonstrated safety and efficacy. Ruxolitinib was particularly successful at controlling splenomegaly and constitutional symptoms, suggesting an additional therapeutic option in patients presenting with such symptoms. Final combined phase 1/2 data will be reported soon.CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Padron E, DeZern AE, Niyongere S, Ball MC, Balasis M, Ramadan H, et al. Promising results of a phase 1/2 clinical trial of ruxolitinib in patients with chronic myelomonocytic leukemia. Blood. 2017;130(Suppl 1):162.Google Scholar
- 66.Ma Y, Rix LR, Zhang Q, Balasis ME, Komrokji RS, Rix U, et al. Pacritinib (PAC) synergistically potentiates azacitidine (5AZA) cytotoxicity in chronic myelomonocytic leukemia (CMML). Blood. 2015;126(23):1658.Google Scholar
- 67.Buonamici S, Yoshimi A, Thomas M, Seiler M, Chan B, Caleb B, et al. H3B-8800, an orally bioavailable modulator of the SF3b complex, shows efficacy in spliceosome-mutant myeloid malignancies. Blood. 2016;128(22):966.Google Scholar
- 68.Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24:497–504. https://doi.org/10.1038/nm.4493 https://www.nature.com/articles/nm.4493#supplementary-information,.CrossRefPubMedGoogle Scholar
- 69.Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122(12):1871–9. https://doi.org/10.1002/cncr.29986.CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Patnaik MM, Sallman DA, Sekeres MA, Luger S, Bejar R, Hobbs GS, et al. Preliminary results from an open-label, phase 2 study of tipifarnib in chronic myelomonocytic leukemia (CMML). Blood. 2017;130(Suppl 1):2963.Google Scholar
- 71.Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007;109(10):4158–63. https://doi.org/10.1182/blood-2006-07-035725.CrossRefPubMedGoogle Scholar
- 72.Patnaik MM, Gupta V, Gotlib JR, Carraway HE, Wadleigh M, Schiller GJ, et al. Results from ongoing phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia. Blood. 2016;128(22):4245.Google Scholar
- 73.23rd Congress of the European Hematology Association Stockholm, Sweden, June 14–17, 2018. HemaSphere 2018;2(S1):1–1113. https://doi.org/10.1097/hs9.0000000000000060.
- 76.Giagounidis A, Platzbecker U, Germing U, Götze K, Kiewe P, Mayer KT, et al. Luspatercept treatment leads to long term increases in hemoglobin and reductions in transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from the phase 2 PACE-MDS extension study. Blood. 2015;126(23):92.Google Scholar
- 77.Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5(2):e63–72. https://doi.org/10.1016/S2352-3026(18)30002-4.CrossRefPubMedGoogle Scholar